- Home
- CCG vs IMUX Comparison
CCG vs IMUX Comparison
Compare CCG & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCG | IMUX |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | China | United States |
| Employees | 548 | 66 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.5M | 75.2M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CCG | IMUX |
|---|---|---|
| Price | $0.78 | $1.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $350.00 | $4.25 |
| AVG Volume (30 Days) | 66.6K | ★ 2.9M |
| Earning Date | 03-30-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $0.51 |
| 52 Week High | $1.54 | $1.51 |
Technical Indicators
Market Signals| Indicator | CCG | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 61.03 |
| Support Level | $0.74 | $0.61 |
| Resistance Level | $0.81 | $1.51 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 70.58 | 45.45 |
Price Performance
Historical ComparisonAbout CCG Cheche Group Inc.
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services and other services in China.. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.